1 |
ICV270 |
9.62 | 67.93% | 14.16% |
virus: 3C-like protease | P0DTD1 | SARS-CoV-2 3CL(IC50=0.97µM) |
2 |
ICV380 |
8.31 | 74.32% | 11.18% |
virus: Helicase | P0DTD1 | SARS RNA(IC50=5.6µM); SARS(EC50=8.95µM) |
3 |
ICV274 |
7.47 | 71.2% | 10.49% |
virus: Papain-like protease | P0DTD1 | MERS PL(IC50=20µM) |
4 |
ICV68 |
7.1 | 61.36% | 11.56% |
virus: 3C-like protease | P0DTD1 | SARS 3CL(IC50=4.92µM); HCoV-229E 3CL(IC50=4.68µM) |
5 |
ICV155 |
7.06 | 74.85% | 9.43% |
virus: 3C-like protease | P0DTD1 | SARS 3CL(58% inhibition at 10µM) |
6 |
ICV268 |
6.56 | 72.13% | 9.09% |
virus: 3C-like protease | P0DTD1 | SARS-CoV-2 3CL(IC50=21.39µM) |
7 |
ICV430 |
6.45 | 73.9% | 8.73% |
human: Histamine H1 receptor | P35367 | MERS(EC50=11.802µM) Vero E6; SARS(EC50=7.545µM) Vero E6 |
8 |
ICV422 |
6.08 | 68.94% | 8.82% |
human: D(2) dopamine receptor | P14416 | MERS(EC50=9.514µM) Vero E6; SARS(EC50=12.971µM);Vero E6 |
9 |
ICV365 |
6.01 | 73.05% | 8.23% |
virus: Papain-like protease; 3C-like protease | P0DTD1 | SARS PL(IC50=30µM); SARS 3CL(IC50=21.1µM) |
10 |
ICV423 |
6 | 65.08% | 9.22% |
human: D(2) dopamine receptor | P14416 | MERS(EC50=5.758µM) Vero E6; SARS(EC50=6.398µM) Vero E6 |
11 |
ICV204 |
5.99 | 68.69% | 8.72% |
virus: 3C-like protease | P0DTD1 | SARS 3CL(IC50=18.2µM) |
12 |
ICV21(covalent) |
5.81 | 57.48% | 10.11% |
virus: 3C-like protease | P0DTD1 | SARS recombinant 3CL or 3CL(IC50=4.35µM); SARS-CoV-2 3CL(IC50=0.03µM) |
13 |
ICV361 |
5.79 | 72.79% | 7.96% |
virus: Papain-like protease; 3C-like protease | P0DTD1 | SARS PL(IC50=10.7µM); SARS 3CL(IC50=24.8µM) |
14 |
ICV360 |
5.51 | 70.86% | 7.77% |
virus: Papain-like protease; 3C-like protease | P0DTD1 | SARS PL(IC50=1.6µM); SARS 3CL(IC50=89.1µM) |
15 |
ICV362 |
5.43 | 66.71% | 8.13% |
virus: Papain-like protease; 3C-like protease | P0DTD1 | SARS PL(IC50=9.2µM); SARS 3CL(IC50=21.1µM) |
16 |
ICV398 |
5.38 | 77.49% | 6.94% |
virus: RNA-dependent RNA polymerase | P0DTD1 | polymerase extension experiments |
17 |
ICV297 |
5.29 | 71.25% | 7.43% |
virus: Papain-like protease | P0DTD1 | SARS PL(IC50=0.8µM) |
18 |
ICV425 |
5.27 | 57.12% | 9.22% |
human: Dopamine receptor | NA | MERS(EC50=2.5µM) Huh7 cell |
19 |
ICV384 |
5.27 | 71.46% | 7.37% |
virus: Helicase | P0DTD1 | MERS-CoV Helicase activity(IC50=9µM) |
20 |
ICV399 |
5.24 | 74.18% | 7.07% |
virus: RNA-dependent RNA polymerase | P0DTD1 | polymerase extension experiments |